Navigation Links
World AIDS Day Audio Press Conference
Date:11/26/2007

Thursday, November 29, 2007

10:00 a.m. (EST)

A World AIDS Day Call for Changes to PEPFAR's HIV Prevention Strategies

Leading U.S. and African Women's, Faith-based and Youth Rights Organizations Call on Congress to Start Taking Effective Prevention Seriously in Reauthorization of Global AIDS Plan

WASHINGTON, Nov. 26 /PRNewswire-USNewswire/ -- The following was released by the Center for Health & Gender Equity:

When: Thursday, November 29, 2007, at 10:00 a.m. EST

Who: Rev. William G. Sinkford, President, Unitarian Universalist

Association

Serra Sippel, Acting Executive Director, Center for Health

Gender Equity, moderator

Brian Ackerman, International Youth Leadership Council,

Advocates for Youth

Bernice Heloo, President, Society for Women and AIDS in Africa,

Ghana

Promise Mthembu, International Community of Women Living with

HIV and AIDS (ICW), invited

Rev. J.P. Heath, ANERELA, South Africa, invited

What: A World AIDS Day teleconference for international and national news media focusing on how U.S. international HIV prevention policy falls short of meeting the needs of women and youth, and on the steps Congress needs to take during the upcoming reauthorization of the President's Emergency Plan for AIDS Relief (PEPFAR) to address the prevention needs of women and youth.

The next day, on November 30, activists will participate in a march and rally in Washington, D.C. calling on Congress and the Administration to Start Taking Effective Prevention Seriously by taking the necessary steps to address the HIV prevention needs of women and youth worldwide. For more information on this event, visit http://www.pepfarwatch.org/index.php?option=com_content&ta
'/>"/>

SOURCE Center for Health & Gender Equity
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
2. Aspirin Named 8th World Wonder by Majority of Americans
3. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
4. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
5. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
6. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
7. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
8. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
11. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 3Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 4Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Exploring standards to advance microbial genomics 9201 1Exploring standards to advance microbial genomics 9201 2Exploring standards to advance microbial genomics 9201 3Cochlear Americas Announces FDA Clearance of the Cochlear 28TM 29 Baha 28R 29 BP100 Sound Processor the Industrys First Programmable Bone Conduction 51324 1Cochlear Americas Announces FDA Clearance of the Cochlear 28TM 29 Baha 28R 29 BP100 Sound Processor the Industrys First Programmable Bone Conduction 51324 2Cochlear Americas Announces FDA Clearance of the Cochlear 28TM 29 Baha 28R 29 BP100 Sound Processor the Industrys First Programmable Bone Conduction 51324 3Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 51322 1Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 51322 2Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 51322 3
Other Medicine Technology:Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 2Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 3Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 4Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 5Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 6Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 7Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 8Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 7Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 8